Pandemic Assessments

Unlike regional events such as hurricanes, earthquakes, or terrorist attacks, a pandemic is a recurring global event with global implications. Thus, outbreaks of influenza A (H1N1), for example, have underscored the critical importance of effective pandemic planning and response to minimize the potential for human morbidity and mortality, reduce social and economic disruptions, and corporate risk exposures. Organizations are well advised to review their ability to respond to potential disruptions to their operations and protect the well-being of employees — whether caused by pandemic or other unforeseen events.

To meet organizations’ pandemic survival and resiliency planning needs, we design custom solutions. We do not force-fit organizations into plans based on pre-defined templates and checklists; rather, we tailor our industry-specific approach, tools, and knowledge base for each client. We are uniquely qualified to be a trusted risk advisor on pandemic planning and response, leveraging our deep and diverse expertise in risk management, HR consulting, and risk transfer alternatives.  

A typical pandemic preparedness assessment is expected to take approximately one week, depending on the availability of management. It commences with a review of the organization’s current documentation, three to five interviews with senior executives and a roundtable workshop with key stakeholders. Following an analysis of the documentation, interviews, and workshops, we deliver a recommended implementation plan to guide future activities, which may include development of an integrated planning protocol.

Leverage New Discovery Technologies

Research and development must continue to use cutting-edge tools. These include sophisticated modeling techniques such as systems biology and high-throughput data-production technologies—that is, technologies that produce a lot of data quickly, for example, next-generation sequencing, which, within eighteen months, will make it possible to sequence an entire human genome. The wealth of new data and improved analytical techniques will enhance future innovation and feed the drug-development pipeline.

A combination of new, smarter devices and fluid data exchange will enable improvements in clinical-trial design and outcomes as well as greater efficiency. Integrating vast amounts of new data will test a company’s analytical capabilities. To expand their data beyond clinical trials, some leading companies are creating proprietary data networks to gather, analyze, share, and respond to real-world outcomes. 

We support the implementation of large projects, including initiatives to develop new products and build new companies. Our teams develop strategies to help innovations come to life, launch new products, and bring them to market. We have helped chemicals companies set up efficient research and development units and adopt benchmarking processes to assess the performance of innovative solutions. Our support extends to implementing major programs, where we work closely with clients to ensure execution.


Executive Leadership

Mr. David Solomon

Mr. David Solomon

Mrs. Linda Colette

Mrs. Linda Colette

Division of Operations

We help defense ministries, intelligence agencies, and other national-security organizations address their most difficult challenges and important opportunities.